Answers are grounded in this paper and cite their sources.
INTRODUCTION Diabetic kidney disease (DKD) refers to kidney damage caused by diabetes mellitus and is one of the most common and serious microvascular complications in patients with diabetes mellitus. DKD is also the main cause of end-stage renal disease. In recent years, the morbidity and mortality of DKD have been rapidly increasing globally. According to the non-communicable disease (NCD) Risk Factor Collaboration,[1] it is expected that the number of patients with diabetes mellitus will reach 1.31 billion by 2050—of which about 30%-40% will develop DKD and 5%-10% will ultimately develop end-stage renal disease, indicating a heavy burden on the global society and economic development. Western medicine treats DKD mainly by controlling blood glucose and blood lipids and reducing proteinuria to slow down disease progression, but the therapeutic effect is poor. Therefore, exploring the mechanisms that may lead to DKD has become an important problem that needs to be urgently solved in the field of nephropathy. Histone modifying enzymes play the dual roles of “switch” and “memory” in DKD, and they can affect chromatin morphology and function through methylation, acetylation, phosphorylation and ubiquitination. Continuous enzyme activation leads to podocyte damage, mesangial matrix expansion, and renal interstitial fibrosis. Inhibition of key enzymes, such as ubiquitously transcribed tetratricopeptide repeat on chromosome X (Utx, Kdm6a) and JMJD1C (KDM3C), can reverse these modifications and reduce the lesions. Our previous RNA-seq assay of endothelial cells induced by hyperglycemia and hypoxia revealed that the histone demethylase family, especially the Jumonji domain-containing (JMJD) protein family, plays an important role in DKD.[2] The JMJD protein can do so by affecting the methylation status of specific proteins—which in turn activate or inhibit gene transcription and lead to pathological forms of DKD, such as inflammation, fibrosis and cellular senescence. INFLAMMATION Inflammation is a defense response of living tissues to damage factors, and its function is mainly to remove damage factors, necrotic tissues and cellular debris, to initiate the process of tissue repair, and to maintain the stability of the internal environment. Inflammation plays a crucial role in DKD. A hyperglycemic environment activates multiple inflammatory pathways, such as the nuclear factor kappa-B signaling pathway. This pathway induces renal cells to produce proinflammatory cytokines and chemokines, attracting immune cells to infiltrate and triggering a localized inflammatory response in the kidney. Inflammatory mediators released by inflammatory cells can damage glomerular mesangial cells and podocytes, destroying the integrity of the glomerular filtration membrane and leading to increased proteinuria. Studies in recent years have found epigenetic regulation, especially histone demethylation, plays a key role in controlling inflammatory gene expression.[3,4] For example, in a DKD mouse model, elevated Jmjd1a (Kdm3a) expression promoted downstream activation of the transforming growth factor β/Smad 2/3 axis, which in turn induced inflammatory injury in kidney tissues. In addition, high expression of Utx was also able to promote elevated expression of inflammatory factors (interleukin-1β and interleukin-6) and p53 in renal tissues, exacerbating DNA damage and promoting inflammation.[3,4] FIBROSIS Fibrosis is usually the end stage of many chronic kidney diseases. During renal fibrosis, epithelial mesenchymal transition (EMT) is a common cellular phenotypic transformation, through which renal tubular epithelial cells lose their own properties and acquire mesenchymal-like properties. This transformation is accompanied by alterations in cellular properties, gene expression, and cellular behavior. At the same time, EMT transformation is accompanied by downregulation of intercellular adhesion molecules, such as E-cadherin (E-cad), and upregulation of mesenchymal markers, such as α-smooth muscle actin, fibroblast-specific protein 1, fibronectin, collagen, and vimentin. Although methods to inhibit EMT and renal fibrosis in the context of DKD are unknown, the role of histone demethylation in EMT and fibrosis has been demonstrated. It has been demonstrated that Utx expression is significantly upregulated in DKD mouse models, which could exacerbate the EMT and tubular dysfunction of the renal tubular epithelial cells in DKD by inhibiting E-cad expression.[3,5] On the other hand, Utx can promote the activation of the transforming growth factor β1/Smad 2/3 axis and exacerbate inflammatory and fibrotic injury of renal tissues in DKD. In addition, histone demethylase JMJD1A can further activate downstream connective tissue growth factor transcription and aggravate fibrotic injury in DKD by binding to myocardin-related transcription factor A. It can also inhibit downstream nuclear receptor subfamily 4A1, which promotes the activation of fibrogenic factors and exacerbates the fibrotic damage of DKD.[6,7] Our previous study also confirmed that JMJD1C can exacerbate EMT injury and renal fibrosis by activating the downstream expression of specificity protein 1, promoting the transcription of zinc finger E-box-binding homeobox 1 and thus inhibiting E-cad expression.[8] These studies suggest that histone demethylases in the JMJD family, including JMJD1A, JMJD1C, and UTX, play a vital role in exacerbating renal fibrosis in DKD. Therefore, targeting these histone demethylases is critical for DKD treatment. For example, treatment with histone demethylase inhibitors GSK-J4 (Histone Lysine Demethylase Inhibitor VIII, targeting UTX and JMJD3) and JIB-04 (JHDM Inhibitor VII, targeting JMJD1C and JMJD3) significantly inhibited the EMT transformation of renal tubular epithelial cells and fibrotic damage of renal tissues in DKD mice and protected renal function.[8,9] CELLULAR SENESCENCE Cellular senescence refers to the fact that cells enter an irreversible growth stagnation state under the influence of intrinsic or extrinsic factors, but the cells do not die and remain metabolically active. In DKD, cellular senescence plays a critical role. Microenvironmental factors (e.g., hyperglycemia, oxidative stress, and inflammation) can induce senescence of renal intrinsic cells, such as glomerular mesangial cells, podocytes, and tubular epithelial cells. Senescent cells secrete various senescence-associated secretory phenotype factors (e.g., inflammatory factors, chemokines, and proteases), which can further exacerbate the inflammatory response, extracellular matrix accumulation, and the fibrotic process in the kidney. In addition, cellular senescence leads to decreased renal cell number and tissue repair capacity, which affects the normal function of the kidneys and promotes DKD progression. Chen et al.[4] noted that UTX can exacerbate cellular DNA damage by promoting elevated p53 expression, leading to cell growth arrest and aggravating the onset of senescence. Our previous research also found JMJD3 can exacerbate DKD renal senescence by inhibiting the expression of peroxisome proliferator-activated receptor γ, which in turn upregulates the expression levels of p53 and p21 and inhibits klotho activation.[10] In contrast, treatment with GSK-J4, which targets both UTX and JMJD3, inhibited the onset of renal senescence in DKD mice. Traditional Chinese medicine (TCM) has unique advantages in treating kidney diseases due to its multicomponent and multitarget characteristics. A large number of clinical trials and animal experiments have demonstrated that TCM has a protective effect on renal function in DKD. Our experiments and those of other researchers have also shown that TCM and its natural extracts can exert anti-inflammatory, anticellular senescence, and antifibrotic effects by targeting and regulating the expression levels of histone demethylases such as JMJD1A, JMJD1C, and JMJD3, thereby protecting renal function and delaying DKD progression [Figure 1].[3,8,10] However, most current studies are not sufficiently extensive. Further research should be conducted by integrating modern multi-omics technologies and data analysis methods to clarify the possible molecular mechanisms of JMJD family regulation in DKD and further explore small-molecule drugs and effective active components of TCM that can effectively intervene in JMJD family activity, providing new research evidence for the clinical prevention and treatment of DKD.Figure 1.: Mechanism of JMJD family in diabetic kidney disease. (Drawn by Figdraw). JMJD, jumonji C (JmjC) domain; DKD, diabetic kidney disease; TCM, traditional Chinese medicine; IL-6, Interleukin-6; IL-1β, Interleukin-1 beta; UTX, ubiquitously transcribed tetratricopeptide repeat on chromosome X; SP1, specificity protein 1; ZEB1, zinc finger E-box binding homeobox 1; CTGF, connective tissue growth factor.Financial support and sponsorship This work was supported by the National Natural Science Foundation of China (82374271), Guangdong Basic and Applied Basic Research Foundation (2023A1515012539), and the Fifth Batch of National Training Programs for Clinical Excellence in Traditional Chinese Medicine (National Traditional Chinese Medicine Human Education Letter [2022] No. 1).
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: